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Diabetes is a pathological condition characterized by relative insulin
deﬁciency, persistent hyperglycemia, and, consequently, diffuse
micro- and macrovascular disease. One therapeutic strategy is to
amplify insulin-secretion capacity by increasing the number of the
insulin-producing β cells without triggering a generalized prolifera-
tiveresponse.Here,wepresentthedevelopmentofasmall-molecule
screening platform for the identiﬁcation of molecules that increase
β-cell replication. Using this platform, we identify a class of com-
pounds [adenosine kinase inhibitors (ADK-Is)] that promote replica-
tion of primary β cells in three species (mouse, rat, and pig).
Furthermore, the replication effect of ADK-Is is cell type-selective:
treatment of islet cell cultures with ADK-Is increases replication of
βcellsbutnotthatofαcells,PPcells,orﬁbroblasts.Short-terminvivo
treatment with anADK-Ialsoincreases β-cell replicationbut not exo-
crine cell or hepatocyte replication. Therefore, we propose ADK in-
hibition as a strategy for the treatment of diabetes.
chemical screening | regeneration
T
ype 2 diabetes mellitus (T2DM) is a progressive disorder of
glucose homeostasis that results in diffuse vascular disease
and end-organ dysfunction. Although multiple pharmacological
therapies for T2DM exist, none of these, as single agents or in
combination, prevents the progressive decline in β-cell function
or the macrovascular disease complications associated with
T2DM (1, 2). Over the next 25 years, the incidence of diabetes is
expected to double and reach a prevalence of 25% in the United
States, making evident the need for effective new therapies (3).
Insufﬁcient β-cell mass is increasingly recognized as a primary
defect in T2DM that contributes to an impaired insulin-secretion
capacity (4, 5). The potential therapeutic role of increasing the
insulin-secretion capacity of an individual is highlighted by the
successful treatment of insulin-dependent type 1 diabetic patients
with pancreatic islet transplantation (6–8). However, the ability to
restore the endogenous β-cell mass of an individual has not been
achieved. Indeed, β cells possess a signiﬁcant proliferative capacity
in rodents and, potentially, in humans (9–11). Studies by our lab-
oratory and others have demonstrated that simple self-duplication
is the primary source of new β cells in mice (12–15). Although
sources of new β cells other than self-duplication have been in-
dicated under speciﬁc circumstances such as pancreatic duct liga-
tion and near-complete β-cell ablation, the potential to harness
these sources for β-cell generation is uncertain (16–19). Although
the majority of human β-cell proliferative capacity may be lost with
age, and the origin of new adult human β cells remains controver-
sial, limited levels of human β-cell replication are observed in
association with metabolically demanding conditions and human-
to-mouse islet transplantation studies (20–24). Hence, the identi-
ﬁcatio nofametho dtoenhanceβ-cellreplicationisofgreatinterest.
Despite the therapeutic potential of a factor that can safely in-
crease the β-cellmass ofan individual, no such biological entity has
been unambiguously established; initial optimism that glucagon-
like peptide receptor (GLP-1R) agonists might be capable of re-
storing islet β-cell mass has not been sustained (25, 26). Previously,
a chemical screen for inducers of β-cell replication was performed
with the intent of ﬁnding compounds for the treatment of T2DM
(27). Unfortunately, this study did not identify compounds with
β-cell-selectivereplication-promoting activity. Therefore,itislikely
that these molecular targets have an unacceptable risk proﬁle for
use in vivo. One explanation for why only nonspeciﬁc mitogenic
compounds were found is that the screen was performed on a re-
versibly transformed cell line that may no longer retain metabolic
characteristicsofprimaryβcells.Here,wepresentthedevelopment
of a screen for compounds that speciﬁcally promote primary β-cell
replication. Using this platform, we have identiﬁed a class of
compounds that selectively increase β-cell division and reveal
a metabolic governor of β-cell proliferation.
Results
Development and Performance of a High-Throughput Primary β-Cell
Replication Assay. To identify compounds that increase β-cell rep-
lication, we developed a screening platform using freshly isolated
rat islet cells (Fig. 1A). Although the use of primary cells limits the
supply of β cells and might be expected to introduce variability
between culture preparations, this approach maximizes retention
of in vivo metabolic characteristics pertinent to the mitotic be-
havior of β cells. Our cultures contained ∼75% β cells/δ cells
(pancreatic and duodenal homeobox 1; PDX-1
+), ∼18% α cells
(glucagon
+), ∼3% ﬁbroblasts (vimentin
+), and ∼5% other cell
types (Fig. 1B). Although the mixed cell type composition of our
culture complicates analysis of β-cell replication, the presence of
multiple cell populations within a single well is also advantageous
asitallowsonetodeterminewhethercompoundtreatmenthasaβ-
cell-selective effect: an important feature of a useful therapeutic.
We used the transcription factor PDX-1 to identify β cells (28).
Although PDX-1 is expressed by both β and δ cells, the vast ma-
jority of PDX-1
+ cells are insulin
+ β cells (Fig. 1C). We used nu-
clear PDX-1 staining as our primary β-cell marker because islet
cells grow in dense irregular clusters that cause a cytoplasmic stain,
such as insulin, to be ambiguously associated with multiple nuclei.
As a result of this ambiguity, ki-67
+ nuclei from rapidly replicating
cells such as ﬁbroblasts have the potential to be incorrectly attrib-
uted to insulin
+ cells. The basal in vitro β-cell replication rate
showed moderate inter-experiment variability (0.4–3.5%) and was
typically higher than the in vivo β-cell replication rate (0.8 ± 0.2%)
of animals of a similar age, as determined by the percentage of
PDX-1
+ cells that coexpressed ki-67.
Adenosine Kinase Inhibitors Promote β-Cell Replication. We screened
∼850 compounds from a carefully selected library of cell-perme-
able bioactive compounds for their ability to increase β-cell
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+ cells that
coexpressed ki-67 (Fig. S1). Although replication rates were de-
termined using automated image acquisition and analysis, dividing
PDX-1
+ cells (yellow arrows) are easilydistinguished from dividing
PDX-1
−cells(white arrows)by the colocalizationofPDX-1 andki-
67 with visual inspection (Fig. 2A). Two hit compounds were
identiﬁed, both well-characterized adenosine kinase (ADK) inhib-
itors (ADK-Is). 5-Iodotubercidin (5-IT) (CAS 24386–93-4) and
ABT-702 (CAS 214697–26-4) increased the percentage of dividing
PDX cells two- to threefold above the background, independent of
a variable baseline PDX cell replication rate, and have a signiﬁcant
effectonPDXcellnumber(seebelow).Toconﬁrmtheresultsusing
PDX-1toidentifyβcells,similarexperimentswereperformedusing
PDX-1 and insulin costaining to identify β cells (Fig. S2A). Indeed,
insulin
+ cell proliferation is enhanced by ADK-I treatment. To
conﬁrm that ADK is the likely target, we tested additional ADK-Is
for theirability topromote β-cell replication. Two additional ADK-
Is that demonstrate similar efﬁcacies to the primary hit compounds
are shown (Fig. S2 B and C) (29).
Next, we tested the replication effect of ABT-702 on murine and
porcine islets to exclude the possibility that these ﬁndings are
uniquetorat β cells.For the porcine β-cell studies, 2- to 3-y-old pigs
wereselectedtotestwhetherenhancedreplicationwouldbeseenin
olderanimals.Compoundtreatmentofisletcellsfrombothofthese
species and rats caused a dose-dependent induction of PDX cell
replication (Fig. 2B and Fig. S3 A and B). Although 5-IT is more
potent than ABT-702, both compounds have a maximum induction
of approximately two- to threefold. One notable observation is that
the analysis of ABT-702 at concentrations above ∼20 μMi sl i m i t e d
by background ﬂuorescence. In addition, the replicative effect of
these compounds was conﬁrmed using both the mitotic phase
markerphosphohistone-H3(PH3)andbromodeoxyuridine(BrdU)
incorporation (Fig. S3 C–E). The ability of the ADK-Is to cause
a similar induction of β-cell replication across multiple species and
induce the expression or incorporation of multiple replication
markers (ki-67, PH3, BrdU)conﬁrm that these compounds activate
a conserved mitotic pathway in β cells. Furthermore, culturing islet
cells in the presence of the 5-IT for 6 d signiﬁcantly increased the
number of PDX-1
+ cells compared with DMSO-treated cultures
(Fig. 2C). At day 6, the number of PDX cells in the 5-IT-treated
wells had increased by 40% compared with a 20% increase com-
pared to DMSO-treated wells and suggests a change from a basal
replication rate of ∼3% per day to ∼6% per day in our cultures.
ADK Is Expressedbyβ Cells andNegatively Regulatesβ-Cell Replication.
ADKisa member ofthesugarkinase group ofenzymes,composed
of three families (hexokinases, ribokinases, and galactokinases)
that play important roles in cellular metabolism (30). ADK is
a ribokinase that regulates the intracellular and extracellular
adenosine levels through its ability to catalyze the phosphorylation
of adenosine to AMP using ATP as the phosphate donor (31).
Although this enzyme is broadly expressed, it is highly expressed in
the liver and pancreas (32). ADK has two known forms, a long
A
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Fig. 1. Experimental outline and rat islet culture composition. (A) Schematic
outline of the screening protocol used to identify compounds that promote
β-cell replication. Isolated rat islets were rested overnight before being dis-
persed and plated. Islet cultures were allowed 48 h to adhere before a 24-h
compound treatment period. Cultures were then ﬁxed, stained, and ana-
lyzed. (B) Composition of rat islet cultures. Left, Immunoﬂuorescent staining
of dispersed rat islet cells for the β-cell transcription factor PDX-1 (green),
α-cell hormone glucagon (red), ﬁbroblast marker vimentin (yellow), and
DNA (blue) in combination. PDX-1 staining alone is also shown (Left, lower
right corner). Right, Quantiﬁcation (percentage total) of the populations
stained in the left panel. Percentages were obtained by automated image
acquisition (n = 80) and analysis from a representative rat islet preparation.
The SD for all values was <10%. (C) PDX-1-positive cells (blue) express either
insulin (green) or somatostatin (red). (Scale bar: 100 μm.)
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Fig. 2. ADK-Is induce proliferation of rat, mouse, and porcine β cells. (A)
Representative images of DMSO- and 5-IT-treated islet cell cultures; β cells
(PDX-1; green), replicating cells (ki-67; red), and replicating β cells (merged;
yellow). Replicating β cells (yellow arrows) and replicating non-β cells (white
arrows) are identiﬁed. (B) Dose–response curves for rat islet cultures showing
the relationship between β-cell proliferation and compound treatment with
5-IT(Left;EC 50=4.7μM)andABT-702(Right;EC 50=7.0μM).(C)Quantiﬁcation
of β-cell number after treatment with DMSO or 5-IT (2 μM) for 96 and 144 h.
Error bars represent SD; *P < 0.01 compared with the vehicle treatment
condition. See SI Methods for experimental details of cell quantiﬁcation.
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isoform-speciﬁc functions have not been established, cytoplasmic
ADK may preferentially participate in the purine salvage pathway,
whereas the nuclear isoform functions as a global regulator of
methyltransferase reactions via the feedback regulation of adeno-
sine on S-adenosylhomocysteine hydrolase activity (34, 35). In-
hibition of ADK has the dual effect of increasing extracellular
adenosine and inhibiting methyltransferase reactions.
ADK immunostaining of islet cultures revealed nuclear ex-
pression of ADK in β cells. In contrast, ADK staining was in the
cytoplasm, not the nucleus, in ﬁbroblasts and α cells (Fig. 3 A–C).
Although ADK localization in δ cells (somatostatin
+ cells) was
variable, ADK was generally present in the nucleus of these cells
(Fig. 3D). To ensure that our ADK staining was speciﬁc, we
validated our antibody by transient transfection of cells with
a full-length ADK cDNA, which caused strong nuclear expres-
sion (Fig. S4A). ADK expression was also determined in mouse
liver (primarily nuclear), adipose (mixed cytoplasmic and nu-
clear), and muscle (primarily cytoplasmic; we noted high and low
ADK-expressing ﬁber bundles, which may reﬂect the different
muscle ﬁber types) tissue sections (Fig. S4B). The presence of
nuclear staining in β cells, but not α cells, indicates that the long
form of ADK is expressed in β cells and not α cells.
We next tested whether the ADK in β cells acts as a negative
regulator of replication. Lentiviral infection was used to direct
the expression of GFP and either a nonspeciﬁc inhibitory RNA
(RNAi) or one targeted to ADK. The ability of the ADK-directed
RNAi to decrease ADK protein levels was conﬁrmed by Western
blot and immunostaining (Fig. S4 C and D). By infecting ap-
proximately half of the islet cell culture, as determined by GFP
expression, we could separately analyze the PDX cell replication
rate of infected and noninfected cells within the same well. If
ADK acts as a cell-autonomous regulator of β-cell replication,
thenPDXcellsthatreceivethenegativecontrolplasmidandPDX
cells that remained uninfected would have the same replication
rate, whereas PDX cells infected with the ADK-targeted siRNA
virus would have an increased replication rate. Indeed, the results
conﬁrmed this prediction (Fig. 3E). Uninfected PDX cells (Fig.
3E, blue bars) and control infected β cells (Fig. 3E, Left, red bar)
all had the basal proliferation rate of ∼2%. In contrast, PDX cells
that received the ADK-directed siRNA demonstrated a 2.5-fold
increase in their replication rate (Fig. 3E, Right, red bar). This
suggests that ADK is a cell-autonomous negative regulator of
β-cell replication and is likely to be the molecular target of
the ADK-Is.
ADK-Is Promote β-Cell Replication via mTOR Activation. Several sig-
naling molecules have previously been shown to participate in the
regulation of β-cell replication (36–39). To explore the mecha-
nism of ADK-I-dependent β-cell replication, the PDX-1
+ cell
replication rate was measured in islet cultures simultaneously
treated with 5-IT plus a replication-pathway inhibitor (Fig. 4A).
Whereas the p38 mitogen-activated protein kinase (MAPK) in-
hibitor SB203580 caused a small but statistically signiﬁcant in-
crease in β-cell replication, the phosphoinositide 3-kinase (PI3K)
inhibitor wortmannin and the mammalian target of rapamycin
(mTOR) inhibitor rapamycin both suppressed ADK-I-dependent
β-cell replication. Although the SB203580 increased β-cell repli-
cation in conjunction with 5-IT, we did not see this effect when
this compound was tested alone. The inhibitory effects of wort-
mannin and rapamycin suggest that activity of the PI3K/mTOR
signalingpathwaymightmediatetheβ-cellreplicationresponseto
ADK-Is. To test this hypothesis, we treated the rat β-cell line INS-
1E cells with ADK-Is and determined the phosphorylation status
of the ribosomal protein S6 (RPS6), a downstream target of
the mTOR signaling cascade (Fig. 4B) (40). Indeed, treatment
with either 5-IT or ABT-702 resulted in increased in RPS6 pro-
tein phosphorylation. Similar but less-pronounced results were
obtained when intact primary rat islets, which comprise multiple
cell lineages, were treated with ABT-702 (Fig. S5A). Thus, the
molecular mechanism by which ADK-Is promote β-cell replica-
tion is likely via activation of the mTOR signaling pathway. It is
interesting to note that mTOR is both a cytoplasmic and nuclear
kinase, and this may be relevant to the presence of nuclear ADK
within β cells (41).
ADK-Is and Glucose or GLP-1R Agonists Have an Additive Effect on
β-Cell Replication. Hyperglycemia is considered to be a driver of
β-cell proliferation despite relatively little in vitro evidence to
supportthiswidelyacceptedprinciple(42–44).Wetookadvantage
of our β-cell replication platform and demonstrated that glucose
has a concentration-dependent effect on β-cell proliferation (Fig.
4C). However, the response kinetics appears to be different from
that of ADK-Is. Whereas ADK-Is increase ki-67 staining by 24 h,
an effect of glucose is not seen until later (48 h). A distinct
mechanism of action for glucose and ADK-Is is supported by the
additive effect of 5-IT at all of the tested glucose concentrations
(Fig. 4C). The combination of high glucose and 5-IT caused
a ﬁvefold induction of the replication rate above the baseline rate.
TheresultsofthisexperimentindicatethattheadditionofADK-Is
to a hyperglycemic environment might signiﬁcantly increase β-cell
growth in the setting of diabetes. Similar to glucose, GLP-1R
agonists are able to increase β-cell replication (45). In our exper-
imental conditions, GLP-1R agonists only modestly increased
PDX cell replication (∼1.5-fold) compared with 5-IT (∼2.5-fold);
however, the addition of 5-IT to the GLP-1R agonists led to an
*
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D E
Fig. 3. β cells express nuclear ADK, which acts as a cell-autonomous nega-
tive regulator of proliferation. (A–C) Nuclear ADK staining (red) is present in
β cells (insulin; green) (A) but not α cells (glucagon, green) (B)o rﬁbroblasts
(vimentin; green) (C). (D) Somatostatin cells (green) demonstrate variable
intensities of nuclear ADK expression. White arrows identify representative
cells in each image. (Scale bars: 100 μm.) (E) Quantiﬁcation of β-cell repli-
cation after infection with virus containing either a scrambled RNAi se-
quence (Left) or an ADK-directed RNAi sequence (Right). The replication rate
of uninfected cells (blue) and infected cells (red) within the same well were
analyzed separately on the basis of virus-encoded GFP expression. Error bars
represent SEM (n = 8 independent wells); *P < 0.01. See SI Methods for
additional experimental details.
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consistent with ADK-Is acting in a GLP-1-independent manner
and suggest the potential for modulating these two pathways in
combination to increase β-cell replication. A GLP-1-independent
function of ADK-Is is also supported by their inability to similarly
potentiate glucose-stimulated insulin secretion (Fig. S5B).
ADK-Is Selectively Promote β-Cell Replication. We assessed the repli-
cation rate of multiple cell types in our islet culture: pancreatic
polypeptide (PP) cells, α cells, δ cells, and ﬁbroblasts (Fig. 5 A and
B). We expected that δ cells might show increased replication in
response to ADK-Is because, like β cells, δ cells express nuclear
ADK (Fig. 3D), secrete their hormone in response to glucose, and
share the expression of several key transcription factors including
PDX-1 (46). Indeed, δ cells did demonstrate a signiﬁcant increase
in replication in response to ADK-I treatment, whereas ﬁbro-
blasts, α cells, and PP cells did not (Fig. 5B). The replication rate
of PP cells is not shown because their division is extraordinarily
rare in culture. In addition to β cells, hepatocytes also express high
levels of nuclear ADK and, therefore, might be expected to pro-
liferate in response to ADK-Is (Fig. S4B) (35). However, hepa-
tocyte replication is not increased in response to drug treatment
(Fig. 5C). Therefore, the replication effect of ADK-Is is selective
and not solely dependent upon nuclear ADK expression.
ADK-Is Promote β-Cell Replication in Vivo. Encouraged by the
in vitro results, we tested whether ABT-702 could selectively
promote β-cell replication in vivo. ABT-702 was chosen because
of its longer half-life compared with 5-IT (47). Indeed, a single
intraperitoneal (i.p.) injection of ABT-702 resulted in a twofold
increase in BrdU incorporation by PDX-1 cells (Fig. 5 D and E).
Theseresultswere conﬁrmedintwo separatecohorts ofanimals in
which (i) β cells were identiﬁed by the presence of insulin rather
than PDX-1 and (ii) replicating cells were identiﬁed by the pres-
ence of ki-67 rather than BrdU (Fig. S6). Notably, treatment with
ABT-702 did not increase the replication rate of exocrine cells,
againhighlightingtheselectivityofADK-Is(Fig.5FandFig.S6A).
In addition, BrdU incorporation by hepatocytes was examined in
response to ABT-702 treatment (Fig. 5G), and these cells did not
show an increased rate of cell division. Therefore, ABT-702 se-
lectively promotes β-cell replication in vitro and in vivo.
Discussion
Historically, T2DM therapies have attempted to augment insulin
secretion (e.g., sulfonylureas) or reduce insulin demand (e.g.,
biguanides, thiazolidinediones) by lowering peripheral resis-
tance. However, T2DM patients appear to have a limited ca-
pacity for adaptive β-cell expansion, and these approaches do not
address this deﬁciency. Here, we present a platform to identify
pharmacological agents that promote increased β-cell division. In
contrast to previously identiﬁed growth-promoting compounds,
which lack cell type speciﬁcity (27, 48, 49), our work identiﬁes
ADK-Is as a class of agents that is capable of promoting β-cell
replication in vitro and in vivo. Of critical importance is that
these compounds preliminarily appear to have a selective pro-
liferation effect on β cells and not α cells, hepatocytes, exocrine
cells, or ﬁbroblasts. The molecular mechanism for β-cell selec-
tivity is not apparent. Although we believe that the presence of
nuclear ADK may be relevant to the observed selectivity, other
cell types, such as hepatocytes, also have nuclear ADK but do
not replicate in response to ADK-Is. We hypothesize that in-
tracellular (possibly nuclear) adenosine levels within β cells ac-
tivate the mTOR pathway with unique consequences within β
cells. A notable limitation of the current study is that we have
tested the proliferative effect of ADK-Is on a restricted number
of cell types. This issue and whether ADK inhibition can pro-
mote the replication of normal and diabetic human β cells will
need to be addressed in future studies.
The primary physiological cue for β-cell replication is thought
to be glucose (44). Because the diabetic condition is deﬁned by
insufﬁcient insulin supply despite excess glucose, diabetes, in
part, represents a failure of the compensatory β-cell response to
excess glucose. Here, we have identiﬁed a pharmacological
stimulus for β-cell replication that is glucose-independent and,
therefore, has the potential to circumvent defects in the glucose-
response pathway. The additive replication effect of ADK-Is and
GLP-1R agonists raises the possibility for simultaneous use of
these agents in the treatment of T2DM. An important question
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Fig. 4. Induction of β-cell replication by ADK-Is is mTOR pathway-dependant
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+-cell replication rates were quantiﬁed in the presenceof DMSO only,
5-ITplus DMSO,and 5-IT plusthesmall moleculeinhibitor indicated below each
bar. Data are shown as the fold increases above the DMSO-only treatment
condition. The inhibitors were used at a concentration of 10 μM( * P < 0.05
compared with the DMSO plus 5-IT treatment condition). (B) Cell lysates were
collected from the rat INS-1E β cell line after a 15-min treatment with the in-
dicated compound. Western blot was performed by serially probing for phos-
phorylated RP-S6 and for total RP-S6 protein (loading control). See SI Methods
for additional experimental details. (C)Q u a n t i ﬁcation of the β-cell replication
rate after culture for 24, 48, or 96 h in the presence of various glucose con-
centrations plus DMSO or 5-IT (2 μM). Values are normalized to the 5 mM glu-
cose plus DMSO treatment condition at each time point. The SD was <10% for
eachtreatmentcondition.Errorbarsarenotshown;*P<0.01when5-ITtreated
wellsarecomparedwithDMSOtreatedwellsatthesameglucoseconcentration
and time point;**P< 0.01when DMSOor5-ITtreated wells arecomparedwith
the 5 mM glucose-treated condition at the same time point and with same
treatment (DMSO or 5-IT). (D)Q u a n t i ﬁcation of the β-cell replication rate after
treatment with DMSO, 5-IT, Ex4 (exendin 4), GLP-1, 5-IT plus Ex4, and 5-IT plus
GLP-1 for 24 h. The concentration of 5-IT was 2 μM. The concentrations of Ex4
and GLP-1 were 20 nM (light colors; Left) and 4 nM (dark colors; Right). Values
normalized to the DMSO treatment condition. Error bars represent SD; *P <
0.01 and **P < 0.03 for the indicated comparisons.
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glucose tolerance by augmenting β-cell mass in rodents and
humans. To answer this experimental question, it may be nec-
essary to develop ADK-Is with improved potency (the identiﬁed
compounds are active in the 1–10 μM range) and less central
nervous system accessibility to avoid central nervous system
effects that have been observed with ADK inhibition (50).
Although inhibition of ADK causes cellular efﬂux of adenosine,
we do not believe that the growth-promoting effect of ADK-Is on
PDX-1
+ cells is mediated by paracrine/autocrine adenosine sig-
naling (51). First, we observe a cell-autonomous increase in β-cell
proliferation in response to ADK knockdown. If this effect were
mediated by extracellular adenosine, a paracrine effect would be
anticipated. Second, the addition of adenosine receptor agonists
andantagoniststhatwereincludedinourscreeninglibrarieshadno
effect onβ-cellproliferationinourassay.Third,β-cellreplicationin
response to ADK-Is requires mTOR activity. Interestingly, prior
work has suggested that mTOR activity is directly inﬂuenced by
cellular ATP levels and that mTOR can be found in the nucleus of
normalcells (41,52).Whetherthenuclear localizationofADK inβ
cells and the primary function of ADK in maintaining nucleotide
pools is relevant to the mechanism of mTOR activation and the
inductionofβ-cellreplicationbyADK-Isremainstobedetermined.
The identiﬁcation of ADK as a regulator of β-cell replication is
an unexpected ﬁnding that highlights the value of using chemical
screening to reveal new biology. The methodology established
here using primary islet β cells may be usefully applied toward the
identiﬁcation of compounds that promote the regeneration of
other tissues such as cardiac myocytes and neurons, which dem-
onstrate limited postnatal cellular division.
Methods
Islet Isolation and Primary Screen Protocol. Rat (250-g Sprague–Dawley;
Charles River) and mouse (12-wk-old animals; C57BL/6; Jackson Laboratory)
islets were isolated as described previously (53). The use of animals was
approved and carried out in accordance with our institutional animal care
and use committee. Porcine islets from retired breeders were provided by
VitaCyte. Islets were incubated (37 °C; 5% CO2) overnight in islet media [99–
786-CV (Mediatech); 10% (vol/vol) FBS serum (Valley Biomedical; BS3033); 8.3
mM glucose (Sigma; G7528); 1× penicillin/streptomycin (Invitrogen; 15070–
063); 1× Glutamax (Invitrogen; 35050–079)]. The following morning, islets
were trypsinized into cellular clusters of 1–3 cells, resuspended in islet media
and plated into the wells of a 96-well plate (Sigma; CLS3904) that had been
coated with 804G (a rat bladder carcinoma cell line) conditioned media. The
cellular plating density was 70,000 cells/well, and >95% viability was con-
ﬁrmed at the time of plating. The islet cells were allowed 48 h to adhere; at
which time, the media were changed [as above, except 2% (vol/vol) serum,
5 mM glucose], and the cells were compound-treated. For screening, com-
pounds were tested at 1 and 10 μM concentrations in duplicate on a single
occasion. After 24 h of compound treatment, cells were ﬁxed with fresh 4%
(wt/vol) paraformaldehyde. See SI Methods for additional details regarding
immunohistochemical and automated replication analysis.
Quantiﬁcation of in Vivo Replication. Twelve-week- old C57/B6 female animals
were injected with BrdU (Sigma; B5002; 10 μL/g) and with either ABT-702
(21 mg/kg) or DMSO vehicle. Twenty-four hours posttreatment, the animals
were killed, and the relevant organs were harvested. A similar experiment
was performed in 6-wk-old C57/B6 female animals without BrdU treatment.
In these animals, replication was assessed after 24 h by ki-67 staining. All
experiments were performed with a minimum of four animals per treatment
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Fig. 5. ADK-Is selectively promote β-cell replication in vitro and in vivo. (A)
Representative images used to analyze the replication rates of PP cells
(pancreatic peptide), α cells (glucagon), δ cells (somatostatin), and ﬁbroblasts
(vimentin) present in the in vitro rat islet culture. The molecular marker of
cell identity is red, ki-67 is green, and nuclear staining is blue. The red box
within the glucagon-stained image (Top Right) is a high magniﬁcation view
of two ki-67 and glucagon double positive cells (arrow). (B) Quantiﬁcation of
the in vitro replication rates of δ cells (somatostatin
+; Top Left), α cells
(glucagon
+; Top Right), and ﬁbroblasts (vimentin
+; Bottom Left) after
treatment with DMSO, 5-IT (2 μM), or ABT-702 (15 μM). *P < 0.01 and **P <
0.05 compared with DMSO-treated condition. (C) Quantiﬁcation of the
replication rate of isolated murine hepatocytes grown in the presence of EGF
(40 ng/mL) and HGF (20 ng/mL) plus DMSO or ABT-702 (15 μM). See SI
Methods for additional experimental details. (D) Representative image used
to quantify in vivo replication in animals treated with either DMSO or ABT-
702. Sections were stained for PDX-1 (green), BrdU (red), and DNA (blue). (E–
G) Quantiﬁcation of the in vivo replication rates of islet β cells (E), exocrine
cells (F), and hepatocytes(G). Error bars represent the SD; P values were
obtained using two-tailed t test.
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Sgroup. Every fourth 12-μm section was used for analysis, and a minimum of
2,000 β cells, exocrine cells, and hepatocytes per organ per animal were
counted. Analysis was performed by manual picture acquisition and cell
counting. β Cells were identiﬁed by either PDX-1 staining or insulin staining,
with similar results. Exocrine cells were approximated by counting all nuclei
outside the islet structure. A minority of these cells were not exocrine cells.
Hepatocytes were identiﬁed as DAPI
+ albumin
+ cells (Bethyl Laboratories;
A90-234A). Dividing cells were BrdU
+ (Amersham; RPN202).
Statistics. Data are presented as the means of multiple replicates performed
simultaneously. All of the experimental results presented were repeated
more than twice. Error bars show the SD unless otherwise speciﬁed. Results
were compared using the two-tailed t test. The EC50 was calculated using
nonlinear regression with the highest replication rate constrained.
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